HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Mucosal IL-12 is more effective than systemic IL-12 in augmenting IFN-gamma expression and inhibiting allergic lung eosinophilia in murine lungs.

Abstract
The relative efficacy of mucosal (intratracheal) and systemic (intraperitoneal) delivery of interleukin (IL)-12 was evaluated in a mouse model of allergic lung eosinophilia. Mucosal administration of IL-12 achieved 100- to 600-fold higher bronchoalveolar lavage (BAL) levels of IL-12, but 2- to 10-fold lower serum levels compared to systemic administration. Whereas both mucosal and systemic IL-12 inhibited BAL eosinophil recruitment at high doses (100-1000 ng), only mucosal IL-12 was effective at low doses (1-10 ng). Mucosal, but not systemic, administration of 1000 ng of IL-12 increased interferon (IFN)-gamma expression in BAL cells. In a model of ongoing eosinophilic inflammation, when mucosal or systemic IL-12 doses were initiated prior to peak eosinophilia, further eosinophil recruitment was inhibited. However, when IL-12 treatment was initiated after peak eosinophil recruitment occurred, recovery from eosinophilic inflammation was not facilitated. Our findings are the first to demonstrate that locally administered IL-12 inhibits eosinophil recruitment at 100-fold lower doses than systemic IL-12. The most likely mechanism of this enhanced inhibitory activity is a sustained increase in lung levels of IL-12 that augments IFN-gamma production from BAL cells. We suggest that future studies should evaluate the efficacy of low doses of nebulized IL-12 in inhibiting eosinophilic lung inflammation in asthma.
AuthorsS Sur, B K Choudhury, J S Lam, P Bouchard, J S Wild, N Sur, R Alam, A Sigounas, D Holbert, M R Van Scott
JournalExperimental lung research (Exp Lung Res) Vol. 26 Issue 6 Pg. 457-76 (Sep 2000) ISSN: 0190-2148 [Print] England
PMID11033768 (Publication Type: Comparative Study, Journal Article, Research Support, Non-U.S. Gov't, Research Support, U.S. Gov't, P.H.S.)
Chemical References
  • Adjuvants, Immunologic
  • Allergens
  • RNA, Messenger
  • Interleukin-12
  • Interferon-gamma
Topics
  • Adjuvants, Immunologic (administration & dosage, blood)
  • Allergens (immunology)
  • Animals
  • Asthma
  • Bronchoalveolar Lavage Fluid (chemistry, cytology)
  • Disease Models, Animal
  • Injections, Intraperitoneal
  • Interferon-gamma (biosynthesis, genetics)
  • Interleukin-12 (administration & dosage, blood)
  • Intubation, Intratracheal
  • Lung (drug effects, pathology)
  • Mice
  • Mice, Inbred BALB C
  • Pollen (immunology)
  • Pulmonary Eosinophilia (immunology, pathology, prevention & control)
  • RNA, Messenger (metabolism)
  • Respiratory Mucosa (drug effects)
  • Reverse Transcriptase Polymerase Chain Reaction

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: